Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib in Advanced Solid Tumors and Intrahepatic Cholangiocarcinoma (FOENIX-CCA2)
NCT02052778Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Jul 2014
- Primary completion
- Oct 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 2, open-label trial of futibatinib in solid tumor, cholangiocarcinoma (CCA), intrahepatic cholangiocarcinoma (ICC) and 4 more (8 arms), sponsored by Taiho Oncology. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Jul 2014; status: completed.
02
Drugs
futibatinib
03
Conditions
solid tumorcholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)urothelial carcinoma (UC)central nervous system tumor
Beyond the preview
Go deeper on NCT02052778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052778.